Recent genomic and epigenomic analyses have pointed out the heterogeneity of tumors from a same histopathological group and have identified key oncogenic alterations that enabled the description of novel tumor entities. Thus, pediatric high-grade gliomas (HGG) comprise a heterogeneous group of tumors, including H3 K27M-mutant, H3 G34-mutant, *IDH-*mutant and H3/*IDH*-wildtype HGG. Furthermore, the H3/*IDH*-wildtype HGG group has recently been divided into three molecular entities based on their DNA methylation profile: Receptor tyrosine kinase type I (RTK I) and II (RTKII), and *MYCN*-amplified, the latter representing the most frequent subgroup (41% of cases, 36/87) \[[@CR4]\]. However, the current 2016 WHO classification does not discriminate between them. In addition, data on these entities came from large series collectively deciphering molecular landscape of HGG. Therefore, the HGG-MYCN subgroup remains poorly characterized and clinical, imaging and pathological data are scarce (Supplementary Table S[1](#MOESM1){ref-type="media"}).

We investigated data from five pediatric supratentorial HGG-MYCN diagnosed by DNA methylation profiling at our institution (one case included in \[[@CR7]\]) and we pooled them with methylation class pediatric HGG-MYCN of the literature (*n* = 59) \[[@CR4], [@CR5], [@CR7]\]. Therefore, we analyzed clinical, histopathological and molecular data of pediatric supratentorial HGG-MYCN and compared them to their pontine counterparts \[[@CR9]\] and did a systematic review of four groups of supratentorial pediatric HGG (including 62 H3 K27M-mutant gliomas, 31 H3-G34 mutant gliomas, 44 HGG-RTKI and 16 HGG-RTKII) \[[@CR1]--[@CR8], [@CR10]\].

Clinical data of our cases are summarized in Table S[2](#MOESM2){ref-type="media"}. The median age of pediatric HGG-MYCN (published cases and our own) was 9.0 years (range from 2 to 18) which was lower than H3 K27M (11.0 years) and H3 G34-mutant (13.0 years), RTKI (10.0 years) and RTKII subgroups (10.0 years) \[[@CR1]--[@CR8], [@CR10]\]. This difference was only significant between HGG-MYCN and H3-G34 mutant gliomas (*p* \< 0.001) \[[@CR4], [@CR5], [@CR7], [@CR8]\]. The sex ratio male/female for HGG-MYCN was 1.3 and 3.4, 0.6, 1.2 and 1.3 respectively for H3 G34-mutant gliomas, H3 K27M-mutant gliomas, HGG-RTKI and RTK2 (but without significant difference) \[[@CR1]--[@CR8], [@CR10]\]. HGG-MYCN were mostly located in the hemispheres (31/37 cases with available data, 83.8%), but 5 (13.5%) were thalamic and one arose from the sellar area \[[@CR4], [@CR5], [@CR7]\]. There was a slight predilection for temporal lobes (16/37 cases, 43.2%), which was significantly higher than in other subgroups (*p* \< 0.001).

By imaging, no calcifications were observed and only one tumor was hemorrhagic (Case 5). They were well-circumscribed with meningeal attachment (except for thalamic tumors). They appeared as solid hypercellular masses with a restricted apparent diffusion coefficient (ADC) in the main part of the tumors. They displayed slight peri-lesional edema and homogeneous enhancement after contrast injection (Fig. [1](#Fig1){ref-type="fig"}). These imaging characteristics were quite similar to their pontine counterparts \[[@CR9]\]. Fig. 1Radiological features of two supratentorial HGG-MYCN. First line: Case 3. (**a**) T1-weighted images after contrast media injection, (**b**) T2-weighted images, and (**c**) diffusion-weighted images: a solid lesion with peri-lesional edema, homogeneous enhancement and hypercellularity (apparent diffusion coefficient (ADC) on diffusion weighted images is restricted in the main part of the tumor). Second line: Case 1. (**d**) T1-weighted images after contrast media injection, (**e**) FLAIR-weighted images and (**f**) cerebral blood flow map using arterial spin labeling: a solid and infiltrative lesion with homogeneous enhancement and high cerebral blood flow

The mean/median progression-free survival was 9.3/9.0 months for HGG-MYCN, 8.8/9.0 months for HGG-RTKI, 8.7/6.3 months for supratentorial H3 K27M-mutant HGG and 10.5/10.0 months for H3 G34-mutant HGG without significant differences in univariate analysis (*p* = 0.421) (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR1]--[@CR3], [@CR5]--[@CR8], [@CR10]\]. The mean/median overall survival (OS) was 16.4/16.5 months for HGG-MYCN, 12.0/11.5 months for HGG-RTKI, 13.9/12.0 months for supratentorial HGG-K27M and 17.6/15.0 months for HGG-G34 without significant differences in univariate analysis (*p* = 0.109) (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR1]--[@CR3], [@CR5]--[@CR8], [@CR10]\]. This median OS was significantly longer (*p* \< 0.001) than pontine HGG-MYCN (median OS of 1.5 months, likely due to tumor location) \[[@CR7], [@CR9]\]. Fig. 2Results of the systematic review of supratentorial molecular subgroups of pediatric HGG. **a** There was no significant difference in terms of progression-free survival (PFS) between HGG-MYCN, HGG-RTKI, supratentorial H3 K27M-mutant HGG and H3 G34-mutant HGG in univariate analysis (*p* = 0.421). **b** There was no significant difference in terms of progression-free survival (PFS) between HGG-MYCN, HGG-RTKI, supratentorial H3 K27M-mutant HGG and H3 G34-mutant HGG in univariate analysis (*p* = 0.109). **c** There was a significant difference in terms of overall survival (OS) between supratentorial HGG-MYCN and pontine HGG-MYCN in univariate analysis (*p* \< 0.001)

Histopathological features of all our HGG-MYCN were similar to those described in pontine HGG-MYCN \[[@CR9]\]. These undifferentiated neoplasms presented circumscribed nodules and isolated tumoral cells infiltrating the brain (corresponding to the radiological peri-lesional edema). Leptomeningeal extension was common, (Fig. [3](#Fig3){ref-type="fig"}a and b). The proliferations were highly cellular, composed of alternating spindle and epithelioid cells with prominent nucleoli (Fig. [3](#Fig3){ref-type="fig"}c-e). In all five cases, malignancy was obvious with high mitotic count and proliferation index (mean MIB1 index 66%), necrosis, and microvascular proliferation (Fig. [3](#Fig3){ref-type="fig"}d-f). Immunohistochemical findings are summarized in supplementary Table S[3](#MOESM3){ref-type="media"}. There was no expression of H3K27M, IDH1R132H, Lin28A and a preserved expression of H3K27me3, INI1 and ATRX in all tumors. Tumor cells co-expressed at least one glial and one neuronal marker (Fig. [3](#Fig3){ref-type="fig"}g-i). All these results were in line with the literature (20/25 reported cases were initially diagnosed as primary neuroepithelial tumors --PNET) \[[@CR7]\]. Contrarily to pontine tumors, no pluriphenotypic pattern was observed in the supratentorial location \[[@CR9]\]. In all 5 cases, tumor cells exhibited a strong nuclear and diffuse accumulation of p53 (Fig. [3](#Fig3){ref-type="fig"}j) and *TP53* mutations were found by next-generation sequencing analyses (as in 56.2% of reported cases) \[[@CR5], [@CR7]\]. Interestingly, loss of PTEN expression was constantly observed in all 5 supratentorial HGG-MYCN (Fig. [3](#Fig3){ref-type="fig"}k), contrarily to their pontine counterparts \[[@CR9]\]. Tumor cells presented a preserved expression of ATRX in all 5 cases which was consistent with the reported data (25/26) \[[@CR4]\]. No *hTERT* promoter mutation was observed in the 5 tumors diagnosed at our institution (possibly due to the small size of our series), contrary to 18.7% (6/32) of reported cases \[[@CR4], [@CR5]\]. Fig. 3Histomolecular features of HGG-MYCN. **a** Diffuse and solid proliferation with several nodules infiltrating the brain parenchyma (arrowheads) and the leptomeninge with large vessels (asterisk) (Case 2, HPS, × 100 magnification). **b** Dense proliferation of tumour cells organized in nodules following Virchow-Robin spaces around capillaries (Case 2, HPS, × 250 magnification). **c** Highly cellular and undifferenciated proliferation composed of alternating fascicles and nodules (Case 2, HPS, × 250 magnification). **d** Highly malignant tumor with microvascular proliferation (arrowhead) and necrosis (Case 2, HPS, × 400 magnification). **e** Embryonal proliferation composed of hyperchromatic cells presenting anisocaryotic nuclei with numerous apoptotic bodies (Case 3, HPS, × 400 magnification). **f** Elevated proliferation index (Case 2, MIB, × 400 magnification). **g** Diffuse expression of Olig2 (Case 2, × 400 magnification). **h** Focal expression of GFAP by tumor cells (Case 2, × 400 magnification). **i** Expression of neurofilament in numerous tumor cells (Case 3, × 400 magnification). **j** Nuclear accumulation of p53 (Case 2, × 400 magnification). **k** PTEN loss of expression in tumor cells (endothelial cells as positive internal controls). **l** High-level of MYCN amplification by FISH analysis with *MYCN* locus in green signals and control centromeric in red signals (Case 4). Black scale bars represent 1 mm (**a**), 100 μm (**b**) and 50 μm (C to K)

HGG-MYCN is a DNA methylation defined tumor entity based on clustering analyses, and tumors constituting this methylation cluster often exhibit *MYCN* amplification (52.3% of reported cases, 34/65) \[[@CR4], [@CR7]\]. *MYCN* amplification is easily detectable by FISH analysis and was observed in the 5 tumors diagnosed at our institution (Fig. [3](#Fig3){ref-type="fig"}l). *ID2* amplification is frequently observed in this DNA methylation cluster (72.2%, 26/36 reported HGG-MYCN, including the 5 tumors from our institution), and was reported in one tumor lacking *MYCN* amplification (1/63 cases, 1.6%) \[[@CR4], [@CR7]\] suggesting that *ID2* amplification is characteristic of this methylation class and might help diagnose this entity.

Here, we extend the knowledge of pediatric supratentorial HGG-MYCN and present their clinico-radiological and morpho-immunophenotypes. We recommend systematically adding *MYCN* and *ID2* analyses to the diagnostic molecular panel for pediatric H3/*IDH*-wildtype malignant supratentorial tumors with glioneuronal phenotype. Nevertheless, considering the relatively high proportion of tumors belonging to this cluster lacking *MYCN* amplification, this diagnosis can only be made with certainty by DNA methylation profiling and further investigations are needed to better characterize this entity and identify alternative oncogenic drivers to *MYCN* amplification.
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